Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 …

A Takeno,Y Makari, S Endo, J Matsuyama,R Kawabata, N Sugimoto

user-5f8cf9244c775ec6fa691c99(2018)

引用 0|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要